TS-002702 — Patient safety is always a priority for any healthcare setting. Researchers at Nationwide Children’s Hospital developed the Software Assisted Morbidity and Mortality Conferencing platform that was adopted from a previous paper-managed process. The web-application improves patient safety throug…

TS-002384 — Movement disorders in the United States are often diagnosed after the infant stage. However, early detection and intervention can result in better outcomes. Physical therapists and researchers at Nationwide Children’s Hospital developed the BabySure which detects abnormal movements early on. The device uses color tracking and a depth camera system to track movements in a 2-minute video, which is then compiled to generate a Motor Function Score to compare to typical age-matched peers for early identification or to monitor movement changes in children with known movement impairments.

TS-002380 — Limb-girdle muscular dystrophy (LGMD) is a group of disorders that causes weakness in the arms and legs with proximal muscles being the most affected. Currently, there is no standard of care established for LGMD. Physical therapist and researcher, Lindsay Alfano, PT, DPT, PCS, at Nationwide Children’s Hospital’s Center for Gene Therapy created a survey to further understand current diagnosis and patient care practices for LGMD. The survey is designed for families, patients, caregivers, and individuals to gauge the patient’s background and LGMD history (first diagnosis, more frequently seen healthcare providers, testing done, use of assistive devices, access to therapy, etc.). By understanding LGMD patient care through the patient’s perspective, the survey moves the healthcare field one step closer to establishing the best practices of care for LGMD.

TS-002316 — Musculoskeletal conditions affect 1.71 billion people worldwide. Researchers at Nationwide Children’s Hospitals developed a novel dynamic approach of PET imaging using commercially available fluorine-18-labeled radionuclides to quantify absolute measures of skeletal muscle perfusion. By utilizing 18F-labled radionuclides instead of cyclotron production of oxygen-15 water, the methodology is widely accessible to any healthcare system possessing a PET camera by lowering the costs and limiting the need of highly trained radiopharamcy teams to produce and administer oxygen-15 water. Additionally, the methodology will quantify skeletal muscle perfusion for a wide range of muscoskeletal applications and quantify abnormalties from muscle astrophy: any vascular or muscoskeletal disease resulting from underlying ischemia to muscle, ischemic vascular disease, spinal muscular disease, Charcot-Marie-Tooth, etc.

TS-002315 — The standard human embryonic kidney 293 (HEK293) cell line is widely used in cancer research, vaccine production, adenovirus and adeno-associated viral vectors and gene therapy. Researchers at Nationwide Children’s Hospital have discovered a new use for the HEK293 cell line: generating stable HEK293 cells expressing MiB1-FLAG and hemagglutinin (HA)–ubiquitin. MiB1-FLAG plays a vital role in cell migration and ubiquitin marks HA for degradation and affects its activity. As a result, the HEK293 cells establish a proper immune response, wound repair and tissue homeostasis while attacking hemagglutinin?????

TS-002177 — Researchers at Nationwide Children's Hospital are in the process of developing an Adeno-Associated Virus (AAV) gene therapy for the Eukaryotic Initiation Factor 2B complex (EIF2B5) related Vanishing White Matter Disease (VWM), an inherited pediatric leukodystrophy disease resulting from autosomal recessive mutations in the five subunit genes of EIF2B5. VWM deteriorates the central nervous system’s white matter which affects the brain’s communication and function. Common symptoms include spasticity, ataxia, hypotonia, speech issues, dysphagia, vision and hearing impairments along with cognitive deficits. The research team is evaluating the CSF delivery of AAV serotype 9 that will target astrocytes which are central in VWM pathology in order to constitute potential therapeutic targets. The AAV vectors will provide wildtype copies of EIF2B5 to address the loss of function resultant from mutations.

TS-002176 — In order to effectively treat bacterial infections, a clear understanding of the bacterium’s antibiotic sensitivity is needed. Researchers at Nationwide Children’s Hospital’s Center for Microbial Pathogenesis created a new method to assist in prescribing antibiotics for infections caused by a biofilm to reduce the dosage and the length of antibiotic treatments.

TS-002172 — Current myometers on the market provide inconsistent results, reducing their reliability. Lindsay Alfano, PT, DPT, PCS at Nationwide Children’s Hospital proposed the creation of a new system called Smart Myometry to limit variability and to make strength testing more reliable.

TS-002171 — Approximately 30% of children and adolescents experience chronic pain. Researcher, Vanessa Olbrecht, MD, at Nationwide Children’s Hospital developed the FOREVR VR, a device that aims to help patients learn how to regulate their nervous system by maintaining their breathing and heart rate variability.

TS-002170 — With the lack of replacement tissue for airway reconstruction, researchers at Nationwide Children’s Hospital developed the 3D Printed Tracheal Bioreactor for Partial Decellularization. Their new process, Partial Decellularization, treats allografts for tracheal replacement. During testing of small animal subjects, they found that allografts supported epithelial regeneration. They then 3D printed the Bioreactor for the translation and adaptation of Partial Decellularization to human-sized grafts. As a result, Partial Decellularization with the bioreactor simultaneously removed immunogenic cell types of the trachea while preserving the immunoprotected cartilage. This technology is easily accessible to medical centers who are interested. The creation and assembly of the Bioreactor through 3D printing allows it to be easily sealed, assembled and reduces the risks of contamination making it unlike any other bioreactor on the market.